A hearing on the Novartis patent case was delayed in October after a local drug company objected to the membership of a panel set up to hear Novartis’ appeal against the decision to refuse a patent for its leukemia drug Glivec.
The Madras High Court adjourned the hearing after Hyderabad-based Natco Pharma objected to a government proposal to exclude a technical member from the patent cell of the Intellectual Property Appellate Board (IPAB), which will hear the Novartis appeal.
The government proposed the exclusion after Novartis objected to the appointment of former patent controller general S Chandrasekaran as a technical member of the IPAB. Chandrasekaran was the head of the Indian Patent Office when it rejected Novartis’ original patent application for Glivec in January 2006.
You must be a
subscribersubscribersubscribersubscriber
to read this content, please
subscribesubscribesubscribesubscribe
today.
For group subscribers, please click here to access.
Interested in group subscription? Please contact us.
你需要登录去解锁本文内容。欢迎注册账号。如果想阅读月刊所有文章，欢迎成为我们的订阅会员成为我们的订阅会员。
